Aligos Therapeutics: Alyeska reports 5.64% stake
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Aligos Therapeutics, Inc. (ALGS) is the subject of an amended beneficial-ownership report in which Alyeska Investment Group, L.P., Alyeska Fund GP, LLC, and Anand Parekh report beneficial ownership of 352,472 shares, or 5.64% of the class, as of September 30, 2026. The shares are Common Stock issuable upon exercise of warrants, with shared voting and dispositive power reported.
The position is held by Alyeska Master Fund, L.P.; Alyeska Investment Group, L.P., as investment manager, exercises voting and investment control. Anand Parekh, identified as the investment manager’s chief executive officer, may be deemed a beneficial owner and disclaims beneficial ownership.
Key Figures
Key Terms
beneficially owned financial
warrants financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.